Impact of Obesity on Plasma Natriuretic Peptide Levels
2004/02/09 by Thomas J. Wang, Martin G. Larson, Daniel Levy +5 · 28 citations
Medicine · #Heart Failure Treatment and Management #Cardiovascular Function and Risk Factors #Cardiovascular and exercise physiology
paper · pdf · doi:10.1161/01.cir.0000112582.16683.ea
Abstract
BACKGROUND: The mechanisms linking obesity to hypertension have not been established, but sodium retention and excessive sympathetic tone are key contributors. The natriuretic peptides are important regulators of sodium homeostasis and neurohormonal activation, raising the possibility that obese individuals have an impaired natriuretic peptide response. METHODS AND RESULTS: We examined the relations of plasma B-type natriuretic peptide (BNP) and N-terminal proatrial natriuretic peptide (N-ANP) to body mass index in 3389 Framingham Study participants (1803 women) without heart failure. Multivariable regression analyses were performed, adjusting for clinical and echocardiographic covariates. BNP levels below the assay detection limit and N-ANP levels in the lowest sex-specific quartile were categorized as low. Multivariable-adjusted mean plasma BNP levels in lean (<25 kg/m2), overweight (25 to 29.9 kg/m2), and obese (> or =30 kg/m2) men were 21.4, 15.5, and 12.7 pg/mL, respectively (trend P<0.0001). Corresponding values in women were 21.1, 16.3, and 13.1 pg/mL (trend P<0.001). A similar pattern was noted for plasma N-ANP. Obese individuals had higher odds of having low plasma BNP (multivariable-adjusted odds ratios: men, 2.51; 95% CI, 1.71 to 3.68; women, 1.84; 95% CI, 1.32 to 2.58) and low plasma N-ANP (odds ratios: men, 4.81; 95% CI, 2.98 to 7.76; women, 2.85; 95% CI, 2.01 to 4.04) compared with lean individuals. Diabetes also was associated with low plasma natriuretic peptide levels, and the negative effects of obesity and diabetes on natriuretic peptide levels were additive. CONCLUSIONS: Obese individuals have low circulating natriuretic peptide levels, which may contribute to their susceptibility to hypertension and hypertension-related disorders.
Citations
Cited by
- Obesity, kidney dysfunction, and inflammation: interactions in hypertension
- Contributory Risk and Management of Comorbidities of Hypertension, Obesity, Diabetes Mellitus, Hyperlipidemia, and Metabolic Syndrome in Chronic Heart Failure: A Scientific Statement From the American Heart Association
- Stress-Mediated Abnormalities in Regional Myocardial Wall Motion in Young Women with a History of Psychological Trauma
- Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: determinants and detection of left ventricular dysfunction. [europepmc]
- Association of common variants in NPPA and NPPB with circulating natriuretic peptides and blood pressure. [europepmc]
- Arterial stiffness: a brief review. [europepmc]
- Cardiac natriuretic peptides act via p38 MAPK to induce the brown fat thermogenic program in mouse and human adipocytes. [europepmc]
- Obesity in Older Adults: Epidemiology and Implications for Disability and Disease. [europepmc]
- Prevalence, clinical phenotype, and outcomes associated with normal B-type natriuretic peptide levels in heart failure with preserved ejection fraction. [europepmc]
- Distribution and clinical correlates of the interleukin receptor family member soluble ST2 in the Framingham Heart Study. [europepmc]
- Natriuretic peptides enhance the oxidative capacity of human skeletal muscle. [europepmc]
- Biomarkers in acutely decompensated heart failure with preserved or reduced ejection fraction. [europepmc]
- Insulin signalling mechanisms for triacylglycerol storage. [europepmc]
- Higher natriuretic peptide levels associate with a favorable adipose tissue distribution profile. [europepmc]
- Changes in liraglutide-induced body composition are related to modifications in plasma cardiac natriuretic peptides levels in obese type 2 diabetic patients. [europepmc]
- Obesity and natriuretic peptides, BNP and NT-proBNP: mechanisms and diagnostic implications for heart failure. [europepmc]
- Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms. [europepmc]
- Patient selection in heart failure with preserved ejection fraction clinical trials. [europepmc]
- Racial Differences in Natriuretic Peptide Levels: The Dallas Heart Study. [europepmc]
- Atrial natriuretic peptide in cardiovascular biology and disease (NPPA). [europepmc]
- N-Terminal Pro-Brain Natriuretic Peptide and Heart Failure Risk Among Individuals With and Without Obesity: The Atherosclerosis Risk in Communities (ARIC) Study. [europepmc]
- Enhancing natriuretic peptide signaling in adipose tissue, but not in muscle, protects against diet-induced obesity and insulin resistance. [europepmc]
- Sex Differences and Similarities in Atrial Fibrillation Epidemiology, Risk Factors, and Mortality in Community Cohorts: Results From the BiomarCaRE Consortium (Biomarker for Cardiovascular Risk Assessment in Europe). [europepmc]
- Murine Models of Heart Failure with Preserved Ejection Fraction: a "Fishing Expedition". [europepmc]
- Obesity, kidney dysfunction and hypertension: mechanistic links. [europepmc]
- Sex-related differences in contemporary biomarkers for heart failure: a review. [europepmc]
- Characterization of the inflammatory-metabolic phenotype of heart failure with a preserved ejection fraction: a hypothesis to explain influence of sex on the evolution and potential treatment of the disease. [europepmc]
- Obesity, kidney dysfunction, and inflammation: interactions in hypertension. [europepmc]
Related